6月4日,心通医疗-B(02160)发布公告,宣布公司计划收购上海佐心的剩余49.00%股权。
公告表示,根据2025年5月30日签署的股权转让协议,上海微创心通同意以总价1.71亿元收购上海佐心的35.27%和13.73%股权。此次收购将使上海佐心成为公司的全资附属公司。
公告中提到,收购的代价为1.71亿元,其中包括向微创投资支付的1.23亿元和向上海佐擎支付的4787万元。付款将分期进行,具体包括在股权转让协议签署后15个营业日内支付部分款项,后续款项将在接下来的五年内逐步支付。
此外,公告还提及股东大会将于2025年6月27日召开,主要议程包括建议授出一般授权以回购股份及发行新股,重选退任董事,以及续聘核数师。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.